We found that the carrying of TPCN2 rs35264875:TA was associated with an increased risk of cancer susceptibility (OR: 1.03, 95% CI: 1.01–1.05, P = 0.00138**, vs. A/A) and a decreased risk of cancer metastasis (OR: 0.74, 95% CI: 0.57–0.96, P value = 0.025* vs. A/A). Here, TPCN2 is linked to cancer.